NCT00446758

Trial of Zinc and HIV Progression in Children

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 440 (actual)
• Sponsor: Harvard School of Public Health (HSPH) · Academic / Other
• Sex: All
• Age: 6 Weeks – 60 Months
• Healthy volunteers: Not accepted

Summary

To examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and improves growth.

Detailed description

The purpose of this study is to examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and improves growth.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Zinc	zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.

Timeline

• Start date: 2008-03-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2007-03-13
• Last updated: 2012-09-14

Locations

1 site across 1 country: Tanzania